Alphabet introduces wearable for continuous data collection

Cara Livernois | | Health Exec | Precision Medicine

Verily, a subsidiary of Alphabet, recently introduced its newly developed Verily Study Watch. This wearable was made more for the clinical research rather than the consumer and offers continuous monitoring, making collecting data as easy as ever.

According to a Verily blog describing the wearable, this device will be capable of measuring data on “electrocardiogram (ECG), heart rate, electrodermal activity and inertial movements” by targeting “cardiovascular, movement disorders and other areas.”

Verily hopes the wearable will be used in the continuous collection of data in real-time, allowing for improved research.

Read the full story by clicking the link below:

Why Alphabet's New Wearable Is Significant -- And What They Left Out

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.